Position in NTLA
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$21,036,923
+$14,596,963 QoQ
Shares Held
1,243,317
+147.5% QoQ
Ownership
0.887%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#25
of 330 holders
Holding Since
Sep 2021
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HRT FINANCIAL LP holds $857,639,414 across 185 Biotechnology names. NTLA ranks #12 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
1,089,376 | $81,136,724 | |
| 2 | INSM |
INSMED Inc
|
689,981 | $73,565,774 | |
| 3 | EXEL |
Exelixis, Inc.
|
929,242 | $50,560,057 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
84,634 | $45,444,226 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
178,491 | $43,689,242 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
498,655 | $40,645,369 | |
| 7 | ABVX |
Abivax S.A.
|
270,612 | $36,061,755 | |
| 8 | TGTX |
Tg Therapeutics, Inc.
|
622,603 | $34,205,808 |
All Filings in NTLA
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $21,036,923 | 1,243,317 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $6,439,960 | 502,337 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $6,876,361 | 764,890 | Shares | Defined | 2026-02-12 | |
| 2025-06-30 | $2,076,056 | 221,328 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $626,767 | 88,153 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $377,725 | 32,395 | Shares | Defined | 2025-02-14 | |
| 2021-09-30 | $1,195,678 | 8,913 | Shares | Defined | 2021-11-15 | |
| No filing history on record for this holder in this stock. | ||||||